GleamWall
中文EN

OGEN ORAGENICS INC

Pharmaceutical Preparations · NYSE · SEC CIK 1174940 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY11.8%
TTM EPS YoY-102.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-176.1%
ROA-120.3%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets66.7%
Debt / equity0.00x
Current ratio—
Interest coverage-547.81x

Cash quality & payout

Operating cash flow / net income0.96x
Accruals ratio-4.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$1.58M$1.18M$645,470$670,543$930,894$449,679$341,542$1.67M
SG&A expense$1.02M$1.42M$1.61M$1.83M$2.19M$1.26M$1.68M$1.69M
Operating income-$2.60M-$2.59M-$2.26M-$2.50M-$3.12M-$1.71M-$2.03M-$3.36M
Interest expense$6,555$414$3,727$7,454$7,039$572,310$199,127$10,969
Pretax income-$2.62M-$2.58M-$2.22M-$2.42M-$3.07M-$2.27M-$2.22M-$3.35M
Income tax-$20,526-$46,377-$22,625—————
Net income-$2.60M-$2.53M-$2.20M-$2.29M-$3.07M-$2.27M-$2.22M-$3.35M
EPS (basic)-0.58-0.57-0.51—-1.96-3.10-3.65—
EPS (diluted)-0.58-0.57-0.51—-1.96-3.10-3.65—
Weighted avg. shares (diluted)4.51M4.43M4.30M—1.56M731,817607,208—
Balance sheet
Cash & equivalents$2.23M$3.86M$6.11M$4.40M$11.40M$1.97M$3.42M$864,840
Short-term investments———$4.00M————
Current assets$3.28M$5.49M$7.49M$10.07M$12.71M$2.14M$3.87M$1.47M
Total assets$3.28M$5.49M$7.49M$10.07M$12.71M$2.14M$3.87M$1.47M
Total liabilities$2.19M$1.82M$1.31M$1.79M$2.87M$4.27M$3.73M$1.68M
Shareholders' equity$1.09M$3.67M$6.18M$8.28M$9.83M-$2.13M$137,688-$211,885
Shares outstanding4.51M4.51M4.38M4.27M4.13M822,92721.48M419,003
Cash flow statement
Operating cash flow-$2.03M-$2.19M-$2.20M-$2.84M-$2.98M-$1.31M-$2.11M-$2.02M
Investing cash flow$0$0$4.00M—————
Financing cash flow$396,589-$56,134-$92,004-$168,628$12.41M-$132,963$4.67M-$260,856
Stock-based compensation$25,116$17,583$17,386$611,839$6,040$6,779$17,706$57,683

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.